## RARE: Ultragenyx Pharmaceutical Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -28.3% below STRENGTH zone (4.0-10.0%); PEG unavailable fails VALUE criteria (<1.0); RSI 30 oversold (REVERSION excluded per A/B test). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($18.26)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 2
- **Sentiment:** Bearish (Bullish: 0, Bearish: 2)

**1. Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Ultragenyx Pharmaceutical Inc. (RARE) and Encourages Stockholders to Learn More About the Investigation**
- Source: ACCESS Newswire | 20260105T180850 | Bearish | Relevance: 100%
- Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) following a significant stock price drop. This investigation comes after Ultragenyx announced results from two Phase 3 studies for setrusumab, which failed to meet primary endpoints despite achieving secondary endpoints. The firm is encouraging investors who purchased Ultragenyx securities to join the investigation.

**2. StockWatch: Ultragenyx, Mereo Plummet on Brittle Bone Candidate Failures**
- Source: Genetic Engineering and Biotechnology News | 20260104T190913 | Bearish | Relevance: 100%
- Ultragenyx Pharmaceutical and Mereo BioPharma saw their shares drop significantly after their brittle bone disease candidate, setrusumab, failed to meet primary endpoints in late-phase clinical trials. While the drug showed improvements in bone mineral density, it did not significantly reduce the annualized clinical fracture rate. Both companies announced plans for expense reductions and are evaluating the future of their programs.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 3 ($0.37M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 51.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 3 |

**Top Holders:**
- Vanguard Group Inc: 10.5% (-0.8%)
- JPMORGAN CHASE & CO: 8.3% (+146.0%)
- FMR, LLC: 7.6% (+179.6%)
- Blackrock Inc.: 6.7% (+2.7%)
- Sands Capital Manage: 3.9% (-4.4%)

### Key Risks

1. Elevated short interest (9.2%): bears positioning against stock.
2. Long-term trend broken: trading 31.7% below SMA200.
3. Falling knife pattern: rapid decline without stabilization, catch risk elevated.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

Revenue growth strong at 20% YoY. Institutional flow bullish (6 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $2.2B |
| Beta | 0.15 |
| 52W Range | $18.41 - $46.50 |
| Short Interest | 9.2% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | -0.24 |
| Forward P/E | N/A |
| Current P/E | N/A |
| YoY Growth | N/A |
| EPS Direction | None |

### Technicals

MRS_20 strengthening from -32.5% to -28.3% (+4.2% in 5 days), confirming momentum buildup. Below STRENGTH zone by 32.3pp (needs >4.0% for momentum thesis). AM_20 at -27.7% indicates price below own 20MA trend. Underperforming sector by 30.0pp, stock-specific weakness. Below SMA200 (0.68x), long-term trend not supportive. MACD histogram bearish (-1.28), momentum weakening. RSI oversold at 30, potential bounce setup. OFD pattern: -SLN (Support test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -28.30% (CS: 50) | Weak |
| RSI_14 | 29.7 | Oversold |
| MACD Histogram | -1.28 | Bearish |
| vs SMA20 | 0.723x | Below |
| vs SMA50 | 0.692x | Below |
| vs SMA200 | 0.683x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $22.54
- **Stop Loss:** $18.26 (19.0% risk)
- **Target:** $26.82 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 308
- **Position Value:** $6,942.32
- **Portfolio %:** 6.94%
- **Risk Dollars:** $1,320.00
- **Risk Per Trade:** 1.32%
- **Modifiers:** L1 110% | L2 120% | Combined 1.32x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | RISK_ON (MEDIUM) | 1.10x |
| L2 Sector | TREND (Zone A) | 1.20x |

*RISK_ON regime with strong participation and low volatility. VIX at 14.75 (6th percentile) with breadth at 63.5% signals healthy risk appetite. Fed dovish expectations and AI/semiconductor momentum are primary drivers, though elevated put/call ratio suggests smart money hedging. Focus on quality growth with awareness of potential complacency.*

### Earnings

**Next:** 2026-02-12 (Est: $-1.23)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $-1.21 | $-1.81 | -49.7% |
| 2025Q2 | $-1.32 | $-1.17 | +11.4% |
| 2025Q1 | $-1.64 | $-1.57 | +4.4% |
| 2024Q4 | $-1.27 | $-1.39 | -9.4% |

---
*RULE-based L3 | 2026-01-07 08:25 | MRS_20*